The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review DOI Creative Commons
Min Deng, Xiaoyü Li,

Huiming Wu

et al.

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: May 16, 2025

Colorectal cancer (CRC) is a common malignant tumor. Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1(PD-1) and ligand 1(PD-L1), have shown promising potential in the treatment of CRC. Specific gut microbiota can modulate efficacy ICIs through immune or metabolic pathways. This review summarizes recent advances combined application PD-1/PD-L1 CRC, aiming to provide insights for expanding clinical options We employed systematic search strategy screen relevant literature from databases such as PubMed, EMBASE, Medline, Cochrane Library, Clinical Trial registries, with period covering inception each database October 2024. study includes animal models human trial subjects. Data extraction screening were strictly carried out by two independent researchers. A total 8 studies 5 trials included evaluate effects Tumor types Microsatellite Stability(MSS), Instability-Low(MSI-L), MSI-H Main outcomes tumor volume, weight, incidence; one reported survival. Study durations ranged 20 days 26 weeks. Two used fecal transplantation(FMT), six applied experimental microbial interventions. The ORR primary endpoint.Some also DCR, PFS, OS. targeted Instability-High(MSI-H)/Deficient Mismatch Repair(dMMR), MSS/Proficient Repair(pMMR), lacked molecular subtype specification. All full transplantation; has released preliminary data. regimen combining therapeutic prospects both research, although most are data remain limited. Future should focus on: (1) gene-edited probiotic strains modifications; (2) synergistic multiple probiotics; (3) conducting high-quality, multicenter trials.

Language: Английский

Predicting the risk of lymph node metastasis in colon cancer: development and validation of an online dynamic nomogram based on multiple preoperative data DOI Creative Commons

Longlian Deng,

Lifan Che,

Haibin Sun

et al.

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: May 8, 2025

Predicting lymph node metastasis (LNM) in colon cancer (CC) is crucial to treatment decision-making and prognosis. This study aimed develop validate a nomogram that estimates the risk of LNM patients with CC using multiple clinical data from before surgery. Clinicopathological were collected 412 who underwent Radical resection CC. The training cohort consisted 300 cases, external validation 112 cases. LASSO multivariate logistic regression used select predictors construct nomogram. discrimination calibration evaluated by ROC curve curve, respectively. application was assessed decision analysis(DCA) impact curves(CIC). Eight independent factors associated identified analysis: LN status on CT, tumor diameter differentiation, ulcer, intestinal obstruction, anemia, blood type, neutrophil percentage. online dynamic model constructed has good consistency. AUC 0.834(95% CI: 0.755-0.855) cohort, 0.872(95%CI: 0.807-0.937) Internal showed corrected C statistic 0.810. both set indicated predicted outcome highly consistent actual outcome. DCA CIC indicate practical value. Based various simple parameters preoperatively, can accurately predict patients. high discriminative ability significant improvement NRI IDI potential

Language: Английский

Citations

0
The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review DOI Creative Commons
Min Deng, Xiaoyü Li,

Huiming Wu

et al.

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: May 16, 2025

Colorectal cancer (CRC) is a common malignant tumor. Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1(PD-1) and ligand 1(PD-L1), have shown promising potential in the treatment of CRC. Specific gut microbiota can modulate efficacy ICIs through immune or metabolic pathways. This review summarizes recent advances combined application PD-1/PD-L1 CRC, aiming to provide insights for expanding clinical options We employed systematic search strategy screen relevant literature from databases such as PubMed, EMBASE, Medline, Cochrane Library, Clinical Trial registries, with period covering inception each database October 2024. study includes animal models human trial subjects. Data extraction screening were strictly carried out by two independent researchers. A total 8 studies 5 trials included evaluate effects Tumor types Microsatellite Stability(MSS), Instability-Low(MSI-L), MSI-H Main outcomes tumor volume, weight, incidence; one reported survival. Study durations ranged 20 days 26 weeks. Two used fecal transplantation(FMT), six applied experimental microbial interventions. The ORR primary endpoint.Some also DCR, PFS, OS. targeted Instability-High(MSI-H)/Deficient Mismatch Repair(dMMR), MSS/Proficient Repair(pMMR), lacked molecular subtype specification. All full transplantation; has released preliminary data. regimen combining therapeutic prospects both research, although most are data remain limited. Future should focus on: (1) gene-edited probiotic strains modifications; (2) synergistic multiple probiotics; (3) conducting high-quality, multicenter trials.

Language: Английский

Citations

0